Medicover AB (0RPS) AI Stock Analysis

Medicover AB

(LSE:0RPS)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Organic Revenue GrowthDouble-digit organic growth across Healthcare and Diagnostics indicates broad demand and continued expansion of Medicover’s operating platform. Sustained volume growth can improve network utilization, deepen customer relationships, and support further earnings growth over the next several quarters.

Negative Factors

Elevated LeverageAlthough leverage is improving, debt remains high relative to equity and reduces financial flexibility during a downturn or higher-rate environment. Elevated obligations may constrain discretionary investment, increase sensitivity to weaker cash generation, and limit room for unexpected pressures.

Medicover AB (0RPS) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 43.08B
Dividend Yield: 0.77%
Average Volume (3M): 16.56K
Price to Earnings (P/E): 46.0
Beta (1Y): 0.95
Revenue Growth: 5.73%
EPS Growth: 90.34%
Country: UK
Employees: 49,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Medicover AB Business Overview & Revenue Model

Company Description

Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turke...

Medicover AB Earnings Call Summary

Earnings Call Date:Jul 21, 2026(Q2-2026)|% Change Since:27.61%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call presents a broadly positive performance: double-digit organic revenue growth, continued margin expansion across multiple quarters, strong cash generation, reduced leverage under 3x, Diagnostics and India showing robust top-line momentum, and management reaffirming mid-term targets. Key challenges include start-up losses from new Indian hospitals (EUR 3.2m this quarter), some healthcare margin dilution from tough comparables, membership declines in Romania, and political/reimbursement uncertainties in certain markets. Overall, positive operational and financial trends outweigh the manageable headwinds.

Positive Updates

Strong Top-Line Growth

Group revenue of EUR 640.4 million, organic revenue growth of 11.8% year-on-year, noting a strong comparable base; Healthcare revenue EUR 442.8 million (up 6.9%, organic 12.2%) and Diagnostics revenue EUR 205.1 million (up 8.5%, organic 10.9%).

Negative Updates

India Start-up Losses and Dilutive Margin

Loss from immature Indian hospitals was EUR 3.2 million in the quarter (majority driven by a very large new hospital), and India remains dilutive to group margins while hospital ramp-up continues.

Company Guidance

Management reiterated its mid‑term 2028 targets and commitment to deliver them, specifically organic revenue of €3.25bn and adjusted organic EBITDA of €600m with leverage under 3x, and confirmed they still expect to achieve these milestones; near‑term financial guidance included full‑year CapEx around 6% of revenues (Q2 CapEx €29.7m, 4.6% of revenues; Q2 split ~2/3 Healthcare, 1/3 Diagnostics; maintenance/growth 44/56 this quarter, reverting to ~2/3 growth:1/3 maintenance for the year), a tax‑rate guide of ~26–30% (Q2 ~28%), strengthened liquidity via an RCF increase to €400m (from €300m), and continued focus on margin and cash generation after reporting Q2 revenue €640.4m (organic +11.8%), adjusted EBITDA €109.2m (margin 17.1%), EBIT €51.2m (8% margin, +100bps YoY), EBITDAaL €72.7m (11.3%, +50bps YoY), operating cash flow €73.6m, free cash flow 4.1% of revenues, ROIC 13.6% and leverage at 2.9x (down from 3.1x at year‑end, 3.6x a year ago); dividend of €0.20/share (~€30m) was paid in Q2.

Medicover AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0RPS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CARE	71Outperform	SEK 700.59M	14.12	―	―	12.86%	18.01%
SE:AMBEA	68Neutral	SEK 15.41B	19.38	15.11%	1.43%	13.33%	28.61%
SE:ATT	66Neutral	SEK 16.84B	17.52	―	0.77%	-1.07%	81.76%
SE:ASKER	58Neutral	SEK 27.32B	40.00	―	0.55%	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0RPS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0RPS	Medicover	284.00	30.98	12.24%
SE:ATT	Attendo AB	116.70	36.50	45.51%
SE:AMBEA	Ambea AB	185.10	61.08	49.25%
SE:CARE	Careium AB	28.80	2.50	9.51%
SE:ASKER	Asker Healthcare Group AB	71.20	-16.88	-19.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Medicover AB AI Stock Analysis